

### SUPPLEMENTARY FIGURES AND LEGENDS




#### Supplementary Figure 1. Analysis of RBPJ in myocardium of WT mice.

- a,b) RBPJ protein by mRNA Q-RT-PCR (a) and by Western blot (b) show a slight increase upon TAC in WT hearts. A.U., arbitrary units. Error bars in a indicate s.e.m. n=3 mice for each condition. mRNA levels were normalized to Actb (β-actin) levels (see Methods). Asterisk, P<0.05.</p>
- c-f) WT mice were subjected to TAC (c,d) MI (e,f) or unoperated (inset) and ventricular myocardium analyzed histologically at 14 days post-surgery. Brightfield micrographs showing immunostaining with T6709, an antibody that preferentially recognizes the activated form of RBPJ (brown) (c,e) and fluorescent micrographs showing T6709 (white) counterstained with anti-α-actinin (red) and FITC-LEA (green) (d,f) reveal upregulated nuclear-localized RBPJ after MI or TAC (arrowheads in d and f indicate cardiomyocyte nuclei). Scale bars (c-f), 20 μm.




### Supplementary Figure 2. Myocardial analysis of Notch ligands.

a-d) Histological immunostaining for Jagged-1 (a,b) and Delta-like-4 (c,d,d',d") in left ventricular myocardium after 14 days of TAC or sham operation (control). Scale bars,
 20 μm (a-d') and 5μm (d"). Arrowheads indicate staining in vascular endothelium



### Supplementary Figure 3. Cardiomyocyte and postnatal specific deletion of RBPJ


a,b) Cardiomyocyte-specific inactivation of *Rbpj*. PCR analyses of *Rbpj* exons 6 and 7 in cardiomyocytes (C) and non-cardiomyocytes (NC) isolated from hearts of conditional knockout (cKO, *Myl2*<sup>Cre/+</sup>, *Rbpj*<sup>flox/flox</sup>) and WT (*Myl2*<sup>+/+</sup>, *Rbpj*<sup>flox/flox</sup>) littermates 10 days (a) and 1 month (b) after birth. *Rbpj* deletion occurred in 1 month old, but not in neonatal, hearts.



Supplementary Figure 4. Histological characterization, microvessel staining and coronary vasculature in RBPJ cKO versus WT hearts.

**a-e)** Histochemical staining of cKO (*Myl*2<sup>Cre/+</sup>, *Rbpj*<sup>flox/flox</sup>) and WT (*Myl*2<sup>+/+</sup>, *Rbpj*<sup>flox/flox</sup>) hearts with Masson's trichrome (**a,a'**), PAS (for glycogen accumulation) (**b,b'**) and by Oil red-O (for lipid accumulation) (**c,c'**) using mouse fat (**c inset**) and liver (**b inset**) as positive


- controls. Transmission electron microscopy of a 2 year-old mouse heart from WT (d) and cKO (d') reveals normal myocardial structure and Z-line spacing, quantified in e, consistent with normal myocardial appearance. Scale bar 50µm (a-c'), 2µm (d, d')
- f-i) Microvessel integrity assessed by fluorescent immunostaining of LV anterior wall histological sections. Fluorescence of fibrin/fibrinogen (green), CD31 (red), and DAPI (blue) from WT (f, f'), cKO (g, g') and WT MI (h,h'). Co-localization of fibrin/fibrinogen with CD31 was quantified using Mander's colocalization coefficient (maximum colocalization coefficient=1) (i). A high degree of co-localization reflects the absence of fibrin/fibrinogen deposition outside vessels in the WT and cKO hearts, whereas leakiness was apparent by the lower Mander's coefficient of characteristically leaky vasculature in infarcted myocardium. Scale bars, 50μm (f-h) and 20μm (f'-h'). Error bars indicate s.e.m, n=3 mice (all cases). Asterisk, *P*<0.05.
- j,k) Vessel analysis of aged (23-26 months old) mice. Quantification of microvessel density (ECs per cardiomyocyte) (j) by counting capillaries and cardiomyocytes stained with FITC-LEA and Alexa 568-phalloidin respectively. Error bars indicate s.e.m., n≥4. Asterisk, P<0.05. Coronary vessels of WT (k) and cKO (k') were identified in the whole heart by Microfil polymer infusion (Methods). RCA: Right Coronary Artery; LCA: Left Coronary Artery; LAD: Left Anterior Descending artery. Sclae bar 2mm.
- I,m) Vessel analysis. Coronary vessels were identified on heart sections by smooth muscle staining (red) and endothelial cell (EC) CD31 (green) stain (I, m). Scale bars, 50µm.



Supplementary Figure 5. Analysis of cardiomyocytes size and hypertrophic response in WT and RBPJ cKO mice.


a,b) Hypertrophy morphometric analysis of hearts from 3 month old cKO and WT littermates subjected to 14 days TAC (+) or sham operation (-). Cross sectional area (CSA) of LV anterior wall cardiomyocytes on histological section (a) show comparable values for WT and cKO hearts (b). Sections (a) stain with phalloidin (red), isolectinB4 (green) and Dapi (blue). CSA, cross-sectional area. Error bars indicate s.e.m., n=4. Asterisk, P<0.05.</li>
Scale bar 20μm.

- c) Size frequency distributions of isolated adult ventricular cardiomyocytes from WT and cKO genotypes. Length x width measurements were determined from primary cultures of adult cardiomyocytes of WT (n=65 cardiomyocytes) and cKO (n=64 cardiomyocytes) littermates prepared by the Langendorff perfusion method (see Methods). There was no statistical difference (p=00013, ANOVA, 1-tailed) and overlapping normal distributions (dashed lines) between the WT and cKO genotypes.
- d) Gene expression analyses from 3 month-old cKO and WT littermates subjected to 14 days TAC (+) or sham operation (-). mRNA levels for *NppA* and *NppB* (encoding atrial and brain natriuretic peptides) by Q-RT-PCR (Supplementary Table 5), normalized to β-actin, are not induced at baseline, but upregulated by TAC in both genotypes. For *NppA*, n = 4,6,6,5; *NppB*, n=5,5,7,5 mice; respectively. Error bars indicate s.e.m. Asterisk, *P*<0.05; ns, not significant.




### Supplementary Figure 6. Effect of doxycycline on VEGFA production.

VEGFA<sub>165</sub> protein quantification by ELISA on WT and iNICD heart tissue treated or untreated with doxycycline. No effect on VEGFA production is detected. Error bars indicate s.e.m, n=4 biological replicates in all instances. Asterisk, *P*<0.05.




Supplementary Figure 7. Angiogenic factor gene expression heatmap from cKO and WT isolated adult cardiomyocytes at 21, 6, 3 and  $1\%O_2$  and from adult heart tissue after TAC and MI.


- a) Isolated adult cardiomyocytes prepared from cKO (*MyI*2<sup>Cre/+</sup>, *Rbpj*<sup>flox/flox</sup>) and WT (*MyI*2<sup>+/+</sup>, *Rbpj*<sup>flox/flox</sup>) mice were cultured for 24h at ambient oxygen (21%O<sub>2</sub>) and 6%, 3% and 1% before being processed for Q-RT-PCR analysis (primer list on Supplementary Table 6). Expression of each gene was normalized to the level of *Actb*. Values in heatmap are further normalized to WT cardiomyocytes at 21% O<sub>2</sub> (Inset to left shows color scale) and hierarchically clustered by Cluster3.0 (Gene profiling is from n≥3 biological replicates shown with statistics in Fig. 4a).
- b) Gene expression analysis of 29 secreted angiogenic factors, 3 Notch targets and in heart ventricular tissue and isolated adult ventricular cardiomyocytes from cKO (My/2<sup>Cre/+</sup>, Rbpj<sup>flox/flox</sup>) and WT (My/2<sup>+/+</sup>, Rbpj<sup>flox/flox</sup>) mice by Q-RT-PCR normalized to ActB (primers are listed in Supplementary Table 6). Mouse ventricular tissue was collected from untreated (Baseline, Fig. 2I) or stressed [15 days after transaortic constriction (TAC) or 4 days and 17 days post myocardial infarction (MI)] cKO and WT mice. Volcano plots portray the cKO to WT ratio (X-axis) relative to p-value (Mann-Whitney test). Red and green points indicate statistically significant (P≤0.05, n≥4) induction or repression of gene expression, respectively; blue points indicate no statistically significant difference.



Supplementary Figure 8. HIF1 $\alpha$ , HIF2 $\alpha$  and RBPJ immunofluorescence in isolated adult cardiomyocytes.


a-f) Immunodetection of Hif1α (a,b), Hif2α (c,d) and RBPJ (e,f) on isolated adult cardiomyocytes after 14 hours of cell culture under normoxic (a, c, e) and hypoxic (b, d, f) conditions. Hif1α, Hif2α and RBPJ staining represented in green, phalloidin in red and DAPI in blue. Pictures representative of more than 3 experiments. Scale bars, 50 μm.





Supplementary Figure 9. HIF1 $\alpha$  and HIF2 $\alpha$  cytoplasmic Mander's colocalization coefficient.

Quantification of HIF1 $\alpha$  and HIF2 $\alpha$  immunostaining of cKO and WT heart sections at baseline (from Fig. 4g) co-stained with cardiac  $\alpha$ -actinin (red) and DAPI (blue). Nuclear colocalization of DAPI within HIF1 $\alpha$  or HIF2 $\alpha$  (left graph) and cytoplasmic colocalization of  $\alpha$ -actinin within HIF1 $\alpha$  or HIF2 $\alpha$  (right graph) was calculated using Mander's colocalization coefficient (M2). M1 values shown in Fig. 4g. Error bars indicate s.e.m., n=3 and 4 biological replicates for WT and cKO mice. Asterisk, P<0.05.



### Supplementary Figure 10. Uncropped images of gel chromatography.

Raw images are shown for all display and supplementary figures as indicated.

### **SUPPLEMENTARY TABLES**

### Supplementary Table 1. Survival of Myl2<sup>Cre/+</sup>, Rbpj<sup>flox/flox</sup> mouse line

Myl2<sup>Cre/+</sup>, Rbpj<sup>flox/flox</sup> x Myl2<sup>+/+</sup>, Rbpj<sup>flox/flox</sup>

Cre/+; Flox/Flox	29 (22.8%)
Cre/+; Flox/+	35 (27.5%)
+/+; Flox/Flox	33 (25.9 %)
+/+; Flox/+	27 (21.2%)
Total	127 (100%)

## Supplementary Table 2. Echocardiography measurements from WT and RBPJ cKO before and after 14 days of TAC

	WT	WT-TAC	сКО	cKO-TAC
IVSd (mm)	0.67 <u>+</u> 0.08	0.78 <u>+</u> 0.09	0.62 <u>+</u> 0.02	0.72* <u>+</u> 0.1
LVIDd (mm)	3.67 <u>+</u> 0.33	4.40 <u>+</u> 0.85	3.83 <u>+</u> 0.57	4.41 <u>+</u> 0.68
LVPWd (mm)	0.66 <u>+</u> 0.08	0.82* <u>+</u> 0.10	0.62 <u>+</u> 0.04	0.72* + 0.1
IVSs (mm)	1.2 <u>+</u> 0.16	1.24 <u>+</u> 0.12	1.11 <u>+</u> 0.06	1.14 <u>+</u> 0.13
LVIDs (mm)	1.99 <u>+</u> 0.28	2.98* <u>+</u> 0.96	2.14 <u>+</u> 0.58	3.07* <u>+</u> 0.79
LVPWs (mm)	1.3 <u>+</u> 0.13	1.31 <u>+</u> 0.15	1.15 <u>+</u> 0.18	1.20 <u>+</u> 0.14
HR (bpm)	617.1 <u>+</u> 59	470* <u>+</u> 60	624 <u>+</u> 62	538*# <u>+</u> 69
Ao-ET (ms)	44.2 <u>+</u> 4	56* <u>+</u> 10	46 <u>+</u> 4	51* <u>+</u> 6
Ao-HR (bpm)	629 <u>+</u> 74	488 <u>+</u> 71	599 <u>+</u> 68	539 <u>+</u> 65
%FS	45.7 <u>+</u> 5.9	33.6* <u>+</u> 10.3	44.9 <u>+</u> 7.1	31.2* <u>+</u> 7.5
EDD/PWD	5.6 <u>+</u> 0.56	5.54 <u>+</u> 1.56	6.2 <u>+</u> 1	6.32 <u>+</u> 1.82
VCF (circ/s)	10.38 <u>+</u> 1.57	6.24* <u>+</u> 2.47	9.94 <u>+</u> 1.7	6.19* <u>+</u> 1.66
LVDd/BW	0.10 <u>+</u> 0.01	0.14* <u>+</u> 0.04	0.12 <u>+</u> 0.01	0.143* <u>+</u> 0.021
LVM (d) (mg)	81.9 <u>+</u> 26.5	137* <u>+</u> 34.5	22.4 <u>+</u> 22.4	119.5* <u>+</u> 24.4
P.P.		181.6 <u>+</u> 29.1		192.6 <u>+</u> 29.3
D.P.		119.9 <u>+</u> 36.2		116.5 <u>+</u> 31.9
Gradience		61.6 <u>+</u> 10.7		76.1 <u>+</u> 46.7
∆Mass		1.1 <u>+</u> 3.9		1.2

 $<sup>^{\</sup>ast},$  p<0.05 WT vs WT-TAC and cKO vs cKO-TAC #, p<0.05 WT-TAC vs cKO-TAC

n= 7, 7, 10 and 9 mice for WT, WT TAC, cKO and cKO TAC, respectively

### Supplementary Table 3: *Vegfa* promoter analysis primers and RBPJ and HIF predicted binding sites by whole genome rVista precomputed analysis

#### **TABLE 3a**

GENE	FORWARD (5'-3')	REVERSE (5'-3')
Vegfa	ATCGCGTGCAGTATATG	GCCATAAAACAACGACCT

#### **TABLE 3b**

	RBPJ	HIF
Vegfa	160,243, <b>1422,1478,1522,1541</b> , 2040,2116,4794	1541,1542

Primers used for genomic ChIP PCR analysis on Roche LightCyler 2.0. The primer pairs (a) were at positions -1403 and -1561 relative to the start site of transcription, and spanned predicted RBPJ consensus binding sites located at positions -1422, -1478, -1522, 1541 and HIF predicted binding sites 1541, 1542 (b).

### **Supplementary Table 4. Hemodynamic parameters**

Genotype at 21% O <sub>2</sub> :	WT <sup>Myl2</sup>	cKO Myl2	WT <sup>Myh6</sup>	icKO <sup>Myh6</sup>
Cardiac Output (ml.min)	12.2±0.3	12.1±0.1	13.0±0.3	12.3±0.1
Stroke Volume (μl)	22.3±0.5	21.2±0.2	22.6±0.7	22.6±0.2
Heart Rate (bpm)	561.1±23.2	580.0±6.6	579.4±23.6	541.6±8.0
MAP (mmHg)	120.5±2.2	122.8±2.0	119.8±1.7	119.0±1.8
VR (mmHg.min/ml)	9.9±0.2	10.4±0.6	9.2±0.2	9.8±0.4
Delivery O <sub>2</sub> (ml O <sub>2</sub> /min)	2.2±0.1	2.1±0.0	2.3±0.0	2.2±0.0

Measurements taken at baseline (21%O<sub>2</sub>) showing no significant differences between cKO and icKO compared to their respective controls  $WT^{Myl2}$  and  $WT^{Myh6}$ . Values are means  $\underline{+}$  SEM. MAP, Mean arterial pressure; VR, vascular resistance. n=4 for each group.

# Supplementary Table 5. Primers used for RT PCR gene expression analysis on Roche LightCycler 2.0

GENE	FORWARD (5'-3')	REVERSE (5'-3')	REF. SEQ.
Rbpj	GAATTTCCACGCCAGTTCAC	ATACAGGGTCGTCTGCATCC	NM_001080927.1
NppA	TTGGAGCAAATCCTGTGTAC	CTTCCTCAGTCTGCTCACTC	NM_008725.2
NppB	AAGAGTCCTTCGGTCTCAAG	CCAGGAGGTCTTCCTACACC	NM_008726.4

## Supplementary Table 6. Primers used for RT PCR gene expression analysis on the Applied Biosystem 7900HT with Biorad iQ SYBR Green Supermix in 384-well plates

GENE	FORWARD (5'-3')	REVERSE (5'-3')	REF. SEQ.
Angpt1	TGCACTAAAGAAGGTGTTTTGCT	TGCACAGTCTCGAAATGGTTT	NM_009640
Angpt2	GGAGACCGTCAACAGCTTG	CTTCTTTACGGATAGCAACCGAG	NM_007426
Ctgf	GACCCAACTATGATGCGAGCC	TCCCACAGGTCTTAGAACAGG	NM_010217
Cxcl1	ACTGCACCCAAACCGAAGTC	TGGGGACACCTTTTAGCATCTT	NM_008176
Cxcl2	CCAACCACCAGGCTACAGG	GCGTCACACTCAAGCTCTG	NM_009140
Cxcl5	ATGGCGCCGCTGGCATTTCT	CGCAGCTCCGTTGCGGCTAT	NM_009141
Egf	AGAGCATCTCTCGGATTGACC	CCCGTTAAGGAAAACTCTTAGCA	NM_010113
Fgf1	CAGCTCAGTGCGGAAAGTG	TGTCTGCGAGCCGTATAAAAG	NM_010197
Fgf2	GCGACCCACACGTCAAACTA	TCCCTTGATAGACACAACTCCTC	NM_008006
Fgf6	CAGGCTCTCGTCTTCTTAGGC	TTCACACCCGAAATCTCTCCA	NM_010204
Hgf	ACTTCTGCCGGTCCTGTTG	GGGATGGCGACATGAAGCA	NM_010427
lgf1	CACATCATGTCGTCTTCACACC	GGAAGCAACACTCATCCACAATG	NM_00111127 4
Mmp2	CCTGGACCCTGAAACCGTG	TCCCCATCATGGATTCGAGAA	NM_008610
Mmp9	GCAGAGGCATACTTGTACCG	TGATGTTATGATGGTCCCACTTG	NM_013599
Pdgfa	TGTGCCCATTCGCAGGAAG	GAGGTATCTCGTAAATGACCGTC	NM_008808
Pgf	AGTGGAAGTGGTGCCTTTCAA	GTGAGACACCTCATCAGGGTA	NM_009640
Tgfa	TCTGGGTACGTGGGTGTTC	ACAGGTGATAATGAGGACAGCC	NM_007426
Tgfb1	AGCTGGTGAAACGGAAGCG	GCGAGCCTTAGTTTGGACAGG	NM_010217
Tgfb2	AGAATCGTCCGCTTTGATGTC	TCTGGTTTTCACAACCTTGCT	NM_008176
Tgfb3	GGACTTCGGCCACATCAAGAA	TAGGGGACGTGGGTCATCAC	NM_009140
Thbs1	CCTGCCAGGGAAGCAACAA	ACAGTCTATGTAGAGTTGAGCCC	NM_009141

Supplementary	Information
---------------	-------------

Pag	е	20	

Thbs2	CTGGGCATAGGGCCAAGAG	GTCTTCCGGTTAATGTTGCTGAT	NM_010113
Timp2	GCAACCCCATCAAGAGGATTC	GGGGCCGTGTAGATAAACTCG	NM_010197
Tnf	CAGGCGGTGCCTATGTCTC	CGATCACCCCGAAGTTCAGTAG	NM_008006
Tnfaip2	GGAGGTGGCAGCGGAACGTC	AAGGCGCGCTGGTAGCTCCTC	NM_010204
Tnfsf12	CCGCCAGATTGGGGAATTTAC	AGTCCAAAGTAGGTTAGGAAGGG	NM_010427
Vegfa	CTTGTTCAGAGCGGAGAAAGC	ACATCTGCAAGTACGTTCGTT	NM_001111274
Vegfb	GCCAGACAGGGTTGCCATAC	GGAGTGGGATGATGTCAG	NM_008610
Vegfc	GTGAGGTGTGTATAGATGTGGGG	ACGTCTTGCTGAGGTAACCTG	NM_013599
ActinB	GTGACGTTGACATCCGTAAAGA	GCCGGACTCATCGTACTCC	NM_008808
Slca1	GCAGTTCGGCTATAACACTGG	GCGGTGGTTCCATGTTTGATTG	NM_008827
Hrt1	CCGACGAGACCGAATCAATAAC	TCAGGTGATCCACAGTCATCTG	NM_031199
Hrt2	AAGCGCCCTTGTGAGGAAAC	TCCCCACGTCGATGGTCTC	NM_011577
Hes1	TCAACACGACACCGGACAAAC	ATGCCGGGAGCTATCTTTCTT	NM_009367